Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

NCT02718950 on ClinicalTrials.gov · last registry update 2016-03-24

A small phase 3 — 20 participants, against a typical 424. Its estimated completion date, March 2017, has passed with no update to the record. Primary outcome, as filed: Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Campinas, Brazil
Sponsor type: Other
Enrollment: 20
Started: 2016-06
Primary completion: 2017-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans

Conditions studied

Obesity · Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.